Pyxis Oncology Reports $25.3 Million Net Loss in Latest Quarterly Filing

Pyxis Oncology, Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $25.3 million for the three months ended June 30, 2026, compared to a loss of $18.4 million during the same period in 2025. For the six months ending June 30, 2026, the company recorded a net loss of $48.6 million, up from $39.5 million in the prior year. The increase in losses is attributed to rising operating expenses, which totaled $50.4 million for the first half of 2026, compared to $45.5 million in 2025. Notably, the company did not generate any milestone revenue during the second quarter, a stark contrast to the $2.8 million reported in the same quarter last year.

The company's operating expenses were driven by research and development costs, which amounted to $36.0 million for the first half of 2026, reflecting an increase from $34.2 million in the previous year. This rise is primarily due to increased clinical trial-related expenses associated with the development of its lead product candidate, micvotabart pelidotin (MICVO). General and administrative expenses also rose significantly, totaling $14.3 million for the first half of 2026, up from $11.3 million in 2025, largely due to higher personnel-related costs and severance expenses.

In terms of liquidity, Pyxis reported cash, cash equivalents, and marketable debt securities totaling $33.0 million as of June 30, 2026. The company completed a private placement on July 2, 2026, raising approximately $50 million, which it expects will fund operations into the second quarter of 2027. However, the filing indicates substantial doubt about the company's ability to continue as a going concern without securing additional funding, as its current resources may not be sufficient to cover operational needs over the next 12 months.

Operationally, Pyxis is focused on advancing its clinical pipeline, particularly the MICVO candidate, which is being evaluated in multiple studies for head and neck squamous cell carcinoma. The company has initiated a Phase 1/2 study of MICVO in combination with Merck's KEYTRUDA® and is actively enrolling patients. Despite the promising clinical data reported, the company remains heavily reliant on the success of this lead product candidate, which is still in early-stage development.

Looking ahead, Pyxis Oncology anticipates continued significant expenses as it progresses its clinical trials and seeks regulatory approvals. The company is exploring various funding avenues, including public or private financing and collaboration agreements, to support its ongoing operations and development efforts. The outcome of these efforts will be critical in determining the company's future viability and ability to bring its product candidates to market.